This list contains information about trials that are recruiting people with MS, which was provided to us by the investigators involved. Although we try to keep this list current, it is possible that the trials are no longer enrolling participants. More information on trials recruiting patients is available from the MS Quarterly Report's listing of Current Clinical Trials in MS.

For definitions and abbreviations, see the Glossary, and see Clinical Trial Participation for general information on enrolling in trials. Individuals who are interested in participating in a clinical trial are encouraged to discuss the possibility with their personal physicians.

Please note: To participate, you will have to reside near the facility, as treatment and follow-up visits will be necessary throughout the course of the study. Also, please keep in mind that clinical trials often have strict criteria for enrollment, specifying the type of people (disease type, duration, age, etc.) they are seeking to participate. These help to ensure that the results will be as reliable and as effective as possible.

Multiple States, Centers

Agent: Antegren® (natalizumab)

Treatment Mode of Action: To affect immune function<

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): Multiple, international

Type of MS: RR

Number of Subjects: 900

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: 1-866-914-6105, active as of 4/12/02

Note: Information on the Connecticut, Illinois and Texas sites for this study is listed below under those locations.

Agent: Antegren® (natalizumab) and Avonex® (interferon beta-1a)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind study of Antegren and Avonex versus Avonex and placebo

Institution(s): Multiple, U.S. and Europe

Type of MS: RR

Number of Subjects: 1200

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: 1-866-914-6105, active as of 4/12/02

Note: Information on the Texas site for this study is listed below under those locations.

Agent: Avonex

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Analysis of effects of Avonex on cognitive symptoms

Institution(s): Multiple, U.S.

Type of MS: RR

Number of Subjects: 120

Funding: Biogen, Inc.

Enrollment Information: msproject1@hotmail.com

 

Agent: Novantrone® (mitoxantrone for injection concentrate)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study to determine tolerability

Institution(s):  Multiple site

Type of MS: Worsening RR, SP

Number of Subjects: 500

Funding: Immunex Corporation

Enrollment Information: goodkind@immunex.com

Note: Information on the New York site for this study is listed below under “New York.”

 

Agent: Novantrone and Avonex or Copaxone®

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study to determine tolerability of combining Novantrone with either Avonex orCopaxone

Institution(s):  Multiple sites

Type of MS: Worsening RR, SP

Number of Subjects: 60

Funding: Immunex Corporation

Enrollment Information: goodkind@immunex.com

Note: Information on the New York site for this study is listed below under “New York.”

 

California

Agent: Androgel™ (testosterone gel)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study for treatment of MS

University of California, Los Angeles

Type of MS: Definite RR or SP, with at least 1 relapse in 2 years prior to entry in study

Number of Subjects: 12 males

Funding: none

Enrollment Information: Ricki Klutch, RN, rklutch@ucla.edu

 

Agent: Avonex

Treatment Mode of Action: To reduce self-injection anxiety

Study Description/Purpose: Blinded study to determine effectiveness of brief cognitive behavioral intervention to treat self-injection anxiety in people taking Avonex.

Institution(s): University of California, San Francisco

Type of MS: RR

Number of Subjects: 40

Funding: Biogen, Inc.

Enrollment Information: Darcy Cox, PsyD, (415) 221-4810, ext. 4962, http://mscenter.ucsf.edu/research.htm

 

Connecticut

Agent: Antegren® (natalizumab)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): Yale MS Research Center, New Haven, and others, international

Type of MS: RR

Number of Subjects: 10-20

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: Jonas Anderson, (203)764-4285 or jonas.anderson@yale.edu

Note: This is one site of a worldwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Agent: CNTO 1275, a human monoclonal antibody

Treatment Mode of Action:  To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study for treatment of MS

Institution: Yale MS Research Center, New Haven.

Number of Subjects: Not available

Funding: Centocor, Inc.

Enrollment Information: Jonas Anderson, (203) 764-4285 or jonas.anderson@yale.edu

 

Agent: Investigational drug (molecule that regulates immune response), name of drug not released

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): Yale MS Research Center, New Haven, and others, international

Type of MS: RR

Number of Subjects: not available

Funding: Bristol-Myers Squibb Company

Enrollment Information: Jonas Anderson, (203)764-4285 or jonas.anderson@yale.edu

Note: This is one site of a worldwide study. Contact information for other sites is listed under Canada, Pennsylvania, and Texas.

 

Agent: Novantrone

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Five-year study of tolerability and safety monitoring for open-label Novantrone infusions.

Institution(s): Yale University School of Medicine, New Haven, CT

Type of MS: worsening RR, SP, PR

Number of Subjects: 20

Funding: Immunex Corporation

Enrollment Information: Jonas Anderson, (203) 764-4285

Note: This is one site of a nationwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Agent: Novantrone

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Prospective study of quality of life and cost of disease in people with MS treated with Novantrone.

Institution(s): Yale University School of Medicine, New Haven, CT

Type of MS: Worsening RR, SP

Number of Subjects: NA

Funding: Immunex

Enrollment Information: Debbie.Ruotolo@yale.edu

 

Agent: Schwann cell (myelin-making cells from peripheral nervous system) transplantation

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Blinded study of safety and effectiveness<

Institution(s):  Yale MS Research Center, New Haven

Type of MS: SP

Number of Subjects: 5

Funding: The Myelin Project

Enrollment Information: msresearch@yale.edu

 

Illinois

Agent: Antegren® (natalizumab)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): University of Chicago and others, international

Type of MS: RR

Number of Subjects: 20

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: Barbara Harding-Clay CMA, CCRC (773)834-4654

Note: This is one site of a worldwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Maine

Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-control study for treatment of MS

Institution(s):   Dartmouth Medical School, Hanover, NH

Type of MS: RR

Number of Subjects: 40-48

Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke

Enrollment Information: kathleen.ryan@dartmouth.edu

 

Maryland

Agent: Betaseron® (interferon beta 1-b) and Imuran® (azathioprine)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study of safety and effectiveness of combination therapy

Institution(s):   University of Maryland, Baltimore, and others

Type of MS: RR, SP

Number of Subjects: 18

Funding: Berlex Laboratories, Inc.

Enrollment Information: pcala001@umaryland.edu

 

Agent: Novantrone and either Avonex or Copaxone

Treatment Mode of Action: Immunosuppressive and Immunomodulatory

Study Description/Purpose: Open-label study to determine safety and effectiveness

Institution(s): University of Maryland, Baltimore, and others

Type of MS: Worsening RR, SP

Number of Subjects: 50

Funding: Investigator sponsored, financial support from Immunex

Enrollment Information: Kerry Naunton, RN, (410) 328-1155

Note: This is one site of a nationwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Massachusetts

Agent: Copaxone and Proventil® (albuterol)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness.

Institution(s): Brigham and Women's Hospital MS Center, Boston        

Type of MS: RR

Number of Subjects: 40

Funding: National Institutes of Health, National Institute of Allergy and Infectious Disease, Autoimmunity Centers of Excellence

Enrollment Information: malbano@partners.org

 

Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-control study for treatment of MS

Institution(s):   Dartmouth Medical School, Hanover, NH

Type of MS: RR

Number of Subjects: 40-48

Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke

Enrollment Information: kathleen.ryan@dartmouth.edu

 

Michigan

Agent: Rebif® (interferon beta-1a), Rebiject™ Mini (autoinjector device)

Treatment mode of action: To affect immune function

Study description: Open-label study comparing the tolerability of Rebif injections with and without the use of Rebiject™ Mini in people with relapsing-remitting MS.

Institution: University of Michigan, Ann Arbor, and others

Type of MS: RR

Number of subjects: No limit

Funding: Serono S.A.

Enrollment information: dmiko@umich.edu

 

Agent: CellCept® (mycophenolate mofetil, an oral immune suppressant currently used to prevent rejection of organ transplants) and Betaseron® (interferon beta 1-b)

Treatment mode of action: To affect immune function

Study description: Open label, randomized, placebo-controlled study, addressing the effectiveness of the combined therapy in MS patients.

Institution: University of Michigan, Ann Arbor

Type of MS: RR

Number of subjects: 30

Funding: Berlex

Enrollment information: dmiko@umich.edu

 

Missouri

Agent: Trimethoprim (antibiotic therapy) and vitamin C

Treatment Mode of Action: To prevent MS relapse with bladder care

Study Description/Purpose: Double-blind, placebo-control study to compare the number of MS relapses in people who receive a bladder infection suppressant versus those who receive placebo and routine bladder care

Institution(s):   Washington University, St. Louis

Type of MS: RR, SP

Number of Subjects:  100 females

Funding: National MS Society

Enrollment Information: lauberj@neuro.wustl.edu

 

Agent: Avonex and intravenous high dose methotrexate

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study of safety and effectiveness of combination therapy

Institution(s):   Consultants in Neurology and MidAmerican Neuroscience Institute, Kansas City

Type of MS: worsening RR, and SP

Number of Subjects: 15

Funding: Biogen, Inc.

Enrollment Information: Ldressman@cinpc.com

 

Agent: Rituxan® (rituximab, molecule that regulates immune response)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study for treatment of MS

Institution(s):   Washington University, St. Louis

Type of MS: RR

Number of Subjects:  30 subjects

Funding: National MS Society

Enrollment Information: lauberj@neuro.wustl.edu

 

Nebraska

Agent: Avonex and pain medication (Tylenol® [acetaminophen], Advil® [ibuprofen] or Aleve® [naproxen])

Treatment Mode of Action: To reduce side effects

Study Description/Purpose: Open-label, randomized study of the use of over-the-counter pain medications to minimize side effects in two groups, those initiating Avonex therapy and those who continue to exhibit side effects after six months on Avonex

Institution(s): University of Nebraska Medical Center, Omaha   

Type of MS: RR

Number of Subjects: 90

Funding: Biogen, Inc.

Enrollment Information: M. Patricia Leuschen, PhD, pleusche@unmc.edu

 

New Hampshire

Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-control study for treatment of MS

Institution(s):   Dartmouth Medical School, Hanover

Type of MS: RR

Number of Subjects: 40-48

Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke

Enrollment Information: kathleen.ryan@dartmouth.edu

 

New York

Agent: Avonex and Prozac® (fluoxetine)

Treatment Mode of Action: To affect immune function and improve symptoms

Study Description/Purpose: Double-blind study to compare the safety and effectiveness of Avonex and Prozac versus Avonex and placebo.

Institution(s): Upstate Clinical Research, LLC, Albany, NY         

Type of MS:  RR

Number of Subjects: 20

Funding: Biogen, Inc.

Enrollment Information: Suzanne Alterman, RN, (518) 533-1500, ext. 546

 

Agent: Copaxone

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study comparing effectiveness in people who have never been treated with Copaxone and people who have not responded to interferon therapy

Institution(s):   Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for MS, New York City, and others

Type of MS: RR

Number of Subjects: 120

Funding: Teva Marion Partners

Enrollment Information: Michele Weber, (212) 241-4264, or multiple.sclerosis@mssm.edu

 

Agent: Novantrone

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Five-year study of tolerability and safety monitoring for open-label Novantrone infusions.

Institution(s): Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for MS, New York City

Type of MS: RR, SP

Number of Subjects: 10

Funding: Immunex Corporation

Enrollment Information: Michele Weber, (212) 241-4264, or multiple.sclerosis@mssm.edu

Note: This is one site of a nationwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Agent: Novantrone and Avonex or Copaxone

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study to determine tolerability of combining Novantrone with either Avonex or Copaxone

Institution(s):   Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for MS, New York City

Type of MS: Clinically Definite

Number of Subjects: 15

Funding: Immunex Corporation

Enrollment Information: Michele Weber, (212) 241-4264, or multiple.sclerosis@mssm.edu

Note: This is one site of a nationwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Ohio

Agent: intensive outpatient rehabilitation

Treatment Mode of Action: To improve symptoms following acute relapses of MS

Study Description/Purpose: Blinded, controlled study to determine effectiveness of physical and occupational therapy following acute relapses of MS

Institution(s): Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland

Type of MS: RR and SP, following acute relapses

Number of Subjects: 160

Funding: National MS Society

Enrollment Information: ivancid@ccf.org

 

Pennsylvania

Agent: Avonex and Imuran

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study to determine safety and effectiveness

Institution(s): Lehigh Valley Hospital, Allentown, PA        

Type of MS: RR

Number of Subjects: NA

Funding: Biogen, Inc.

Enrollment Information: Nancy Eckert, RN, (610) 402-9001, nancy.eckert@lvh.com

 

Agent: Inosine (dietary supplement in oral capsule form)

Treatment mode of action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to

determine safety and efficacy of inosine, and effect of inosine on the

number of newly active lesions.

Institution: University of Pennsylvania, Philadelphia

Type of MS: RR

Number of subjects: 30 subjects

Funding: Thomas Jefferson University

Enrollment Information: Tara Ordille, (215) 662-4893

 

Agent: Investigational drug (molecule that regulates immune response), name of drug not released

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to

determine safety and effectiveness

Institution(s): The University of Pennsylvania, The Hospital of the

University of Pennsylvania-Department of Neurology, and others,

international

Type of MS: RR

Number of Subjects: 6

Funding: Bristol-Myers Squibb Company

Enrollment Information: Tara Ordille (215) 662-4893

Note: This is one site of a worldwide study. Contact information for other

sites is listed under Canada, Connecticut and Texas.

 

South Carolina

Agent: Zocor® (simvastatin), a cholesterol-lowering drug under study for treatment of MS

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Open-label study to determine effectiveness

Institution(s):   Medical University of South Carolina, Charleston, and others

Type of MS: RR

Number of Subjects: not available

Funding: Merck, Inc.

Enrollment Information: Feng Liu, phone - (843) 792-2993, fax - (843) 792-8626, liuf@musc.edu

 

Texas

 

Agent: Antegren® (natalizumab)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): Texas Neurology, PA, Dallas, and others, international

Type of MS: RR

Number of Subjects: 900

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: Janey Phillips, (214) 827-3610, ext. 258

Note: This is one site of a nationwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Agent: Antegren® (natalizumab) and Avonex

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind study of Antegren and Avonex versus Avonex and placebo

Institution(s): Texas Neurology, PA, Dallas, and others, U.S. and Europe

Type of MS: RR

Number of Subjects: 1200

Funding: Biogen, Inc., Elan Corporation plc

Enrollment Information: Janey Phillips, (214) 827-3610, ext. 258

Note: This is one site of a worldwide study. Contact information for other sites is listed above under “Multiple States, Centers.”

 

Agent: Investigational drug (molecule that regulates immune response), name of drug not released

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): Texas Neurology, PA, Dallas, and others, international

Type of MS: RR

Number of Subjects: 330

Funding: Bristol-Myers Squibb Company

Enrollment Information: Janey Phillips, (214) 827-3610, ext. 258

Note: This is one site of a worldwide study. Contact information for other sites is listed under Canada and Italy.

 

Vermont

Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-control study for treatment of MS

Institution(s):   Dartmouth Medical School, Hanover, NH

Type of MS: RR

Number of Subjects: 46-50

Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke

Enrollment Information: kathleen.ryan@dartmouth.edu

 

Virginia

Agent: Avonex

Treatment Mode of Action: To improve attention and concentration deficits

Study Description/Purpose: Open-label study to determine effects of attention and concentration in patients diagnosed with relapsing-remitting MS, receiving initial treatment with Avonex

Institution(s): Neuroscience Consultants, PLC, Reston, VA        

Type of MS: RR

Number of Subjects: 15

Funding: Biogen, Inc.

Enrollment Information: sparlow@nscplc.com

 

International

Canada

Agent: Investigational drug (molecule that regulates immune response), name of drug not released

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind, placebo-controlled study to determine safety and effectiveness

Institution(s): University of Toronto, CANADA, and others, international

Type of MS: RR

Number of Subjects: 330

Funding: Bristol-Myers Squibb Company

Enrollment Information: (416) 864-5206

Note: This is one site of a worldwide study. Contact information for other sites is listed under Connecticut, Pennsylvania, and Texas.

 

France

Agent: 3-4 diaminopyridine

Treatment Mode of Action: To improve fatigue

Study Description/Purpose: Double-blind, placebo controlled study to determine safety and effectiveness

Institution(s): CHU de Rennes, FRANCE

Type of MS: All types

Number of Subjects: 60

Funding: French Health Ministry

Enrollment Information: gilles.edan@chu-rennes.fr

 

Agent: Novantrone and Betaseron

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind study to determine safety and effectiveness

Institution(s): CHU de Rennes, FRANCE, and others in France and Italy

Type of MS: RR

Number of Subjects: 124

Funding: French Health Ministry, Schering AG

Enrollment Information: gilles.edan@chu-rennes.fr

 

Israel

Agent: T cell vaccination

Treatment Mode of Action: To affect immune function

Study Description/Purpose: Double-blind study to determine safety and effectiveness

Institution(s): Hadassah Hospital, Jerusalem, ISRAEL    

Type of MS: RR

Number of Subjects: 30

Funding: Grant for TCV

Enrollment Information: Dr. Dimitrios Karussis, karus@cc.huji.ac.il

 

Italy

Agent: computer-assisted cognitive rehabilitation

Treatment Mode of Action: To improve memory, attention

Study Description/Purpose: Randomized, double-blind study

Institution(s):   Multiple sites

Type of MS: all

Number of Subjects: 120

Funding: National MS Society

Enrollment Information:  Alessandra Solari, MD, solari@istituto-esta.it